Clinical trial Recruiting at 1 site Interventional Ages 18 to 65

Using brain stimulation to reduce cravings and improve control in people with substance use disorders

Official title: Modification of Inhibitory Control and Craving Through Transcranial Direct Current Stimulation (tDCS) as an Add-On Treatment for Substance Use Disorder

Run by Central Institute of Mental Health, Mannheim · NCT06959342 · Data updated 2026-11-12

This study is testing if a type of brain stimulation can help people with alcohol use disorder feel less cravings and have better control during their detox treatment.

Quick facts

Study typeInterventional
Ages18 Years to 65 Years
SexAll
Enrollment162 (estimated)
SponsorCentral Institute of Mental Health, Mannheim
Academic / other
Locations2 sites (Mannheim and 1 other locations)
StatusRecruiting
StartedSeptember 23, 2024
Main results expectedMarch 31, 2027
Study endsSeptember 30, 2027
Registry record updatedJune 4, 2025
Trial IDNCT06959342 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are individuals aged 18 to 65 with a primary diagnosis of alcohol use disorder who are undergoing detoxification treatment.

Probably not a fit

Patients with severe psychiatric comorbidities or those currently experiencing severe withdrawal symptoms may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project investigates the use of transcranial direct current stimulation (tDCS) to enhance inhibitory control and reduce cravings in individuals with substance use disorders, particularly focusing on alcohol use disorder. Participants aged 18 to 65 undergoing detoxification treatment will receive different tDCS protocols, including active and sham conditions, to determine the most effective settings for improving treatment outcomes. The study will assess cognitive performance through neuropsychological testing and EEG recordings to identify optimal stimulation parameters. The goal is to enhance the effectiveness of standard detoxification treatments by integrating tDCS as an adjunctive therapy.

Why it matters

Potential benefit: If successful, this approach could lead to improved treatment outcomes, including longer periods of abstinence and reduced substance use after relapse.

How similar studies have gone: While there are conflicting findings regarding tDCS effectiveness in substance use disorders, this study aims to clarify its potential benefits, making it a novel approach in this area.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* main diagnosis: alcohol use disorder according to DSM-5
* patients of any gender aged 18 to 65
* normal vision or correctable visual impairment.
* sufficient ability to communicate verbally and in writing
* ability to give fully informed consent after reviewing thorough written information

Exclusion Criteria:

* withdrawal of consent
* severe internal, neurological, or psychiatric comorbidities (e.g., lifetime schizophrenia, bipolar disorder, or other severe mental disorders according to ICD-10 and DSM-5, such as severe depression or PTSD within the last 12 months).
* Exclusion criteria for an EEG/tDCS examination (e.g. metal implants in the head, epilepsy, etc.)
* severe withdrawal symptoms (CIWA-R \> 7)
* alcohol intoxication (breath alcohol concentration \> 0 ‰)
* Pharmacotherapy with psychoactive substances within the last 14 days (exceptions: clomethiazole or benzodiazepines used in withdrawal treatment, provided they were discontinued at least 3 days prior; antidepressants or anxiolytics taken at stable doses).
* drug or alcohol use within the last 7 days
* for women: pregnancy
* suicidal tendencies or danger to others

Where it's running

  • Central Institute of Mental Health
    Mannheim, Germany
    Recruiting
  • Psychiatrisches Zentrum Nordbaden (Psychiatric Center Nordbaden)
    Wiesloch, Germany
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.